Open AccessCombining protein arginine methyltransferase inhibitor and anti-programmed death-ligand-1 inhibits pancreatic cancer progression
Author(s) -
Nannan Zheng,
Min Zhou,
Fei Sun,
Manxiu Huai,
Yi Zhang,
Chun-Ying Qu,
Feng Shen,
Leiming Xu
Publication year - 2020
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v26.i26.3737
Subject(s) - cancer research , pancreatic cancer , arginine , methyltransferase , ligand (biochemistry) , apoptosis , cancer , chemistry , medicine , biology , microbiology and biotechnology , biochemistry , methylation , receptor , amino acid , gene
Immunotherapy targeting programmed death-1 (PD-1) or programmed death-ligand-1 (PD-L1) has been shown to be effective in a variety of malignancies but has poor efficacy in pancreatic ductal adenocarcinoma (PDAC). Studies have shown that PD-L1 expression in tumors is an important indicator of the efficacy of immunotherapy. Tumor cells usually evade chemotherapy and host immune surveillance by epigenetic changes. Protein arginine methylation is a common posttranslational modification. Protein arginine methyltransferase (PRMT) 1 is deregulated in a wide variety of cancer types, whose biological role in tumor immunity is undefined.